| CD22-CART |
|
Phase Ⅰ |
Shanghai Hrain Biotechnology |
Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma |
Details
|
| AUT-O3 |
AUTO-3 |
Phase Ⅱ |
University College London, Autolus |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
| Anti-CD22 CAR-T cell therapy (No. 307 Hospital) |
|
Phase Ⅱ |
No 307 Hospital of the Chinese People’s Liberation Army |
Acute lymphoblastic leukaemia (ALL) |
Details
|
| SM-03 |
SM-03; SM-06 |
Phase Ⅱ |
Lonn Ryonn Pharma, SinoMab Bioscience Ltd |
Non-Hodgkin's lymphoma (NHL) |
Details
|
| Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) |
LCAR-L10D |
Phase Ⅰ |
Second Affiliated Hospital of Xi'an Jiaotong University, Nanjing Legend Biotech |
Diffuse large B cell lymphoma |
Details
|
| JCAR-018 |
JCAR-018 |
Phase Ⅰ |
National Cancer Institute, Opus Bio, Juno Therapeutics |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas |
Details
|
| RD-102 |
RD-102 |
Phase Ⅰ |
Nanjing IASO Biotherapeutics |
Lymphoblastic leukaemia, Diffuse large B cell lymphoma |
Details
|
| BAY-1862864 |
BAY-1862864 |
Phase Ⅰ |
Bayer |
Non-Hodgkin's lymphoma (NHL) |
Details
|
| Epratuzumab |
AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2,AMG412,CDP3194,IMMU103,IMMU1903,IMMUhLL2 |
Phase Ⅲ |
Immunomedics, UCB |
Sjoegren's syndrome, Systemic lupus erythematosus, Acute lymphoblastic leukaemia (ALL) |
Details
|
| GTB-1550 |
DT-2219ARL; DT-2219; IND-100780; OXS-1550 |
Phase Ⅱ |
University of Minnesota, Oxis International, GT Biopharma |
B-cell lymphoma, Leukemia |
Details
|
| Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
Phase Ⅱ |
M.D. Anderson Cancer Center |
Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
| Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase Ⅰ |
University of Texas Southwestern Medical Center, Galileo Research |
B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) |
Details
|
| Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
B-cell lymphoma, Leukemia |
Details
|
| Epratuzumab I-131 |
|
Phase Ⅱ |
Immunomedics, Repligen |
Non-Hodgkin's lymphoma (NHL) |
Details
|
| UCART-22 |
UCART-22 |
Phase Ⅰ |
Cellectis |
Acute lymphoblastic leukaemia (ALL) |
Details
|
| Pinatuzumab vedotin |
DCDT-2980S; FCU-2703; RG-7593; RO-5541072; RO-5541072-000; ACD22-VCMMAE |
Phase Ⅱ |
Genentech |
Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) |
Details
|
| CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase Ⅰ |
PersonGen Biomedicine |
B-cell lymphoma |
Details
|
| Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase Ⅰ |
Seattle Children's Hospital |
Acute lymphoblastic leukaemia (ALL) |
Details
|
| Anti-CD22-CAR T cell therapy (Kecellitics Biotech) |
|
Phase Ⅱ |
Kecellitics Biotech Company Ltd |
Leukemia, Lymphoma |
Details
|
| Anti-CD22 CAR T cell therapy (Shanghai GeneChem) |
|
Phase Ⅰ |
Shanghai GeneChem |
Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas |
Details
|
| Bectumomab |
|
Phase Ⅲ |
Immunomedics |
Non-Hodgkin's lymphoma (NHL) |
Details
|
| CART22-cells |
CART22-cells |
Phase Ⅰ |
University of Pennsylvania, Novartis |
B-cell lymphoma, Leukemia |
Details
|
| Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase Ⅰ |
Shanghai Jiaotong University |
Acute lymphoblastic leukaemia (ALL) |
Details
|
| Chimeric antigen receptor T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine) |
|
Phase Ⅱ |
Shanghai Unicar-Therapy Bio-medicine Technology |
Non-Hodgkin's lymphoma (NHL) |
Details
|
| Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase Ⅰ |
Wuhan Bio-Raid Biotechnology |
B-cell lymphoma, Multiple myeloma (MM) |
Details
|
| Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase Ⅰ |
Stanford University |
B-cell lymphoma |
Details
|
| Epratuzumab Y-90 |
90Y-DOTA-hLL2; 90Y-hLL2; hCD22-Y-90; IMMU-102 |
Phase Ⅱ |
Immunomedics, Nantes University Hospital |
Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
| Anti-CD22 monoclonal antibody-toxin conjugate (Galileo Research/the University of Texas) |
IMTOX-22 |
Phase Ⅰ |
University of Texas Southwestern Medical Center, Royal Free and University College Medical School, Cancer Research Technology, National Institutes of Health, Galileo Research, Abiogen Pharma |
Non-Hodgkin B-cell lymphomas |
Details
|
| CAT-3888 |
CAT-3888; BL-22 |
Phase Ⅱ |
Cambridge Antibody Technology, National Institutes of Health, MedImmune |
Lymphoblastic leukaemia, Chronic lymphocytic leukemia (CLL), Hairy cell leukemia, Non-Hodgkin's lymphoma (NHL) |
Details
|
| RFB4-SMPT-dgA |
RFB4-SMPT-dgA; IgG-RFB4-SMPT-dgA; NSC639179 |
Phase Ⅰ |
National Cancer Institute, University of Texas Southwestern Medical Center |
B-cell lymphoma |
Details
|
| Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
Leukemia, Lymphoma |
Details
|
| TRPH-222 |
TRPH-222; CAT-02-106; CD22-4AP |
Phase Ⅰ |
Catalent, Triphase Accelerator |
B-cell lymphoma |
Details
|
| Anti-CD22 CAR-T cell therapy (iCarTAB BioMed) |
|
Phase Ⅱ |
iCarTAB Biomed |
B-cell lymphoma |
Details
|
| Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology) |
|
Phase Ⅰ |
Yake Biotechnology, The First Affiliated Hospital of Zhejiang University School of Medicine, Beijing Boren Hospital |
Lymphoblastic leukaemia, hematological malignancies |
Details
|
A-Z
